Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07225570 +/- Sasanlimab in NMIBC
NCT05259397Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-07225570 in bladder cancer (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with Dose limiting toxicities at 28 days and Number of Participants with Adverse Events at 24 months. Planned start Mar 2022; status: withdrawn.
02
Drugs
PF-07225570
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05259397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259397.